Precise PEG LLC

10/13/2026

Radionuclide Drug Conjugates (RDCs) - Part 3: Design Principles

With clinical validation now established, the focus of RDC development is shifting from proof-of-concept to architecture optimization. Successful RDC platforms are defined not only by isolated innovations, but by disciplined architectural integration. Target biology, vector pharmacokinetics, radionuclide physics, chelation stability, linker engineering, and manufacturing feasibility must function as a coordinated system.

At Precise PEG, we focus on enabling this architectural precision through advanced chelator-ready intermediates, linker engineering strategies, and conjugation chemistry solutions designed to support stability and scalability in RDC development.

Read the full article of Part 3 at Precise Post: https://precisepeg.com/blogs/posts/radionuclide-drug-conjugates-part-3-design-principles

If you missed it, read Part 1 here: https://precisepeg.com/blogs/posts/radionuclide-drug-conjugates-part-1-basic-information
and Part 2 here: https://precisepeg.com/blogs/posts/radionuclide-drug-conjugates-part-2-clinical-landscapes

09/23/2026

What are Chemical Inducers of Proximity (CIPs)?
Chemical inducers of proximity (CIPs) are small molecules that induce proximity between two proteins, promoting protein–protein interactions and thereby regulating cellular processes. This strategy of artificially bringing two proteins together to elicit a specific biological effect has been widely applied, with well-known examples including PROTACs and molecular glues. Beyond applications involving the ubiquitin–proteasome system and transcription factors, this approach can also be used to induce interactions involving membrane proteins and lysosomal membrane proteins, making it an important strategy in drug design.

In 2023, Gray’s and Crabtree’s groups at Stanford reported a new class of molecules known as transcriptional/epigenetic chemical inducers of proximity (TCIPs). These molecules can recruit endogenous cancer-driving proteins or their downstream transcription factors to the promoters of cell-death genes, thereby activating their expression. (Nature 2023, 620, 417–425.)

Continue to read the entire article on our website:

Chemical inducers of proximity (CIPs) are small molecules that induce proximity between two proteins, promoting protein–protein interactions and thereby regulating cellular processes. This strategy of artificially bringing two proteins together to elicit a specific biological effect has been widel...

01/28/2026

An interest in pSar continues to grow as a PEG alternative, successful implementation relies on precise molecular design and controlled conjugation strategies. At Precise PEG, we support pSar-based bioconjugation through well-defined pSar linkers (https://precisepeg.com/collections/psar-linkers) and customizable linker architectures, enabling partners to translate design concepts into developable conjugates across antibody, protein, and delivery platforms. Read the full article at Precise Post (https://precisepeg.com/blogs/posts/polysarcosine-psar-as-a-peg-alternative-in-bioconjugation)

01/15/2026

We focus on the development and production of glycosidase-cleavable linkers for ADC applications with β-glucuronidase- and β-galactosidase-cleavable designs.

12/04/2025

Season’s Greetings from the Precise PEG team! Wishing you a joyful holiday season and a brilliant start to 2026.

We’re excited to announce fresh additions to our catalog:
New cleavable linkers (including maleimide-pSar and Glu-pSar series
Targeted Protein Degrader (TPD) building blocks including Deuterated reagents
More customizable PEG spacers including multi-arm PEG linkers

As you wrap up your 2025 projects, we’re here to help you finish strong and kick off your 2026 initiatives launch smoothly and quickly. Check out our full catalog here: Products – Precise PEG